Pre-market open on 3/20/25, Adaptimmune (NASDAQ:ADAP) provided a business update for 4Q24 (in lieu of financial results for the quarter/full year to be released in conjunction with the company’s 10-K ...
After the market closed on 3/24/25, Adaptimmune (NASDAQ:ADAP) filed the company’s Form 10-K Annual Report. ADAP reported a net loss of $74.2 million for 4Q24, or $(0.05) per diluted ordinary share ...
Elliot Norry, the Chief Medical Officer of $ADAP ($ADAP), sold 5,584 shares of the company on 01-17-2025 for an estimated $3,243. We received data on the trade from a ...
ADAPTIMMUNE THERAPEUTICS ($ADAP) posted quarterly earnings results on Tuesday, May 13th. The company reported earnings of -$0.18 per share, missing estimates of -$0. ...
Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - ...
Barclays analyst Peter Lawson maintained a Sell rating on Adaptimmune Therapeutics today and set a price target of $0.46. The company’s shares closed yesterday at $0.08. Take advantage of TipRanks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback